Share the post "DII Data:Stock Market Insights on 20 Sep -Concord Biotech"
Below is a summary of the recent activities observed within the Domestic Investments for the clients: Nexpact . Let’s delve into the details below to explore further.
For ONE GLOBAL SERVICE PROVIDER LIMITED, the latest financial data showcases impressive results. The company reported net sales of ₹0.00 million and total income of ₹135.60 million for the quarter. Expenditure was ₹-112.13 million, resulting in a net profit of ₹17.58 million. EPS for continuing operations was ₹2.47. Additional financial details include other income of ₹0.00 million, finance costs of ₹0.00 million, and employee benefit expenses of ₹-3.02 million. Depreciation and amortization expenses were ₹-0.43 million. Current tax was ₹-5.91 million and deferred tax amounted to ₹0.02 million. Total comprehensive income for the period was ₹0.00 million, with other comprehensive income net of taxes at ₹0.00 million.
The company has a market capitalization of ₹95.1 crore and a current stock price of ₹134. Historically, the stock has fluctuated between ₹155 / 29.2. With a Price-to-Earnings (P/E) ratio of 13.4, the stock appears highly valued. The book value per share is ₹20.3, and the dividend yield is 0.00%. The Return on Capital Employed (ROCE) is 84.9% and the Return on Equity (ROE) is 65.6%. The debt-to-equity ratio is very low at 0.02, although the company reports a net cash flow of ₹1.20 crore. The Piotroski score is 7.00, and the Graham Number estimates the intrinsic value of the stock at ₹67.6. The Price-to-Book (P/B) ratio is 6.61, indicating the stock is trading at a premium relative to its book value.
For Concord Biotech Limited, the latest financial data showcases impressive results. The company reported net sales of ₹2,158.02 million and total income of ₹2,261.09 million for the quarter. Expenditure was ₹1,479.42 million, resulting in a net profit of ₹595.93 million. EPS for continuing operations was ₹5.70. Additional financial details include other income of ₹103.08 million, finance costs of ₹2.41 million, and employee benefit expenses of ₹316.64 million. Depreciation and amortization expenses were ₹131.79 million. Current tax was ₹193.94 million and deferred tax amounted to ₹5.34 million. Total comprehensive income for the period was ₹597.62 million, with other comprehensive income net of taxes at ₹1.69 million.
The company's market cap is ₹23,274 crore, with a stock price of ₹2,225. The historical stock range has been between ₹2,664 / 992. Its Price-to-Earnings (P/E) ratio of 74.3 indicates a high valuation. The book value per share is ₹146, and it has a dividend yield of 0.39%. The ROCE is 28.1% and ROE is 21.1%. With a very low debt-to-equity ratio of 0.01, the company is minimally leveraged. However, it reports a negative net cash flow of ₹11.6 crore. The Piotroski score of 8.00 and the Graham Number of ₹314 show mixed financial indicators, while the Price-to-Book (P/B) ratio of 15.2 suggests the stock is trading at a premium.
For Marksans Pharma Limited, the latest financial data showcases impressive results. The company reported net sales of ₹2,545.27 million and total income of ₹2,626.79 million for the quarter. Expenditure was ₹2,203.80 million, resulting in a net profit of ₹320.15 million. EPS for continuing operations was ₹0.71. Additional financial details include other income of ₹81.52 million, finance costs of ₹2.83 million, and employee benefit expenses of ₹231.93 million. Depreciation and amortization expenses were ₹68.36 million. Current tax was ₹103.58 million and deferred tax amounted to ₹-0.74 million. Total comprehensive income for the period was ₹320.86 million, with other comprehensive income net of taxes at ₹0.71 million.
Currently valued at ₹10,876 crore, the company's stock price is ₹240. It has seen a price range of ₹243 / 93.8 over time. The stock's Price-to-Earnings (P/E) ratio is notably high at 32.7, implying a strong valuation. The book value per share is ₹45.6 and the dividend yield is 0.25%. ROCE is recorded at 20.6%, and ROE stands at 16.5%. The company maintains a very low debt-to-equity ratio of 0.12, though it has a negative net cash flow of ₹20.8 crore. The Piotroski score of 4.00 and the Graham Number of ₹86.9 suggest some caution, while the Price-to-Book (P/B) ratio of 5.27 reflects a premium valuation.
| Company Logo | Company | Client Name | Buy/Sell | Qty Traded | Price | Trader Name |
|---|---|---|---|---|---|---|
 |
One Global Service Provider | Nexpact | Buy | 50K | 141.10 | Na |
 |
Concord Biotech | Ubs Principal Capital Asia | Sell | 740K | 2589.86 | The Vanguard Group Inc A/c Vanguard Total International Stock Index Fund |
 |
Marksans Pharma | Vanguard Emerging Markets Stock Index Fund A Series Of Vanguard International Equity Index Funds | Buy | 2M | 316.85 | Graviton Research Capital Llp |
| Vanguard Total International Stock Index Fund | Buy | 2M | 316.85 | Graviton Research Capital Llp |
The 50K shares of One Global Service Provider have been purchased by the by Nexpact through Domestic Investments at a price of ₹141.10 per share.
The 740K shares of Concord Biotech have been sold by the by Ubs Principal Capital Asia through Domestic Investments at a price of ₹2589.86 per shareand it is purchased by The Vanguard Group Inc A/c Vanguard Total International Stock Index Fund at a price of ₹2589.86 per share.
The 2M shares of Marksans Pharma have been purchased by the by Vanguard Emerging Markets Stock Index Fund A Series Of Vanguard International Equity Index Funds through Domestic Investments at a price of ₹316.85 per shareand it is sold by Graviton Research Capital Llp at a price of ₹316.85 per share.
The 2M shares of Marksans Pharma have been purchased by the by Vanguard Total International Stock Index Fund through Domestic Investments at a price of ₹316.85 per shareand it is sold by Graviton Research Capital Llp at a price of ₹316.85 per share.
ONE GLOBAL SERVICE PROVIDER LIMITED
0.00
Net Sales
17.58
Net Profit
135.60
Total Income
-112.13
Expenditure
134
Current Price
95.1
Market Cap
For ONE GLOBAL SERVICE PROVIDER LIMITED, the latest financial data showcases impressive results. The company reported net sales of ₹0.00 million and total income of ₹135.60 million for the quarter. Expenditure was ₹-112.13 million, resulting in a net profit of ₹17.58 million. EPS for continuing operations was ₹2.47. Additional financial details include other income of ₹0.00 million, finance costs of ₹0.00 million, and employee benefit expenses of ₹-3.02 million. Depreciation and amortization expenses were ₹-0.43 million. Current tax was ₹-5.91 million and deferred tax amounted to ₹0.02 million. Total comprehensive income for the period was ₹0.00 million, with other comprehensive income net of taxes at ₹0.00 million.
The company has a market capitalization of ₹95.1 crore and a current stock price of ₹134. Historically, the stock has fluctuated between ₹155 / 29.2. With a Price-to-Earnings (P/E) ratio of 13.4, the stock appears highly valued. The book value per share is ₹20.3, and the dividend yield is 0.00%. The Return on Capital Employed (ROCE) is 84.9% and the Return on Equity (ROE) is 65.6%. The debt-to-equity ratio is very low at 0.02, although the company reports a net cash flow of ₹1.20 crore. The Piotroski score is 7.00, and the Graham Number estimates the intrinsic value of the stock at ₹67.6. The Price-to-Book (P/B) ratio is 6.61, indicating the stock is trading at a premium relative to its book value.
Concord Biotech Limited
2,158.02
Net Sales
595.93
Net Profit
2,261.09
Total Income
1,479.42
Expenditure
2,225
Current Price
23,274
Market Cap
For Concord Biotech Limited, the latest financial data showcases impressive results. The company reported net sales of ₹2,158.02 million and total income of ₹2,261.09 million for the quarter. Expenditure was ₹1,479.42 million, resulting in a net profit of ₹595.93 million. EPS for continuing operations was ₹5.70. Additional financial details include other income of ₹103.08 million, finance costs of ₹2.41 million, and employee benefit expenses of ₹316.64 million. Depreciation and amortization expenses were ₹131.79 million. Current tax was ₹193.94 million and deferred tax amounted to ₹5.34 million. Total comprehensive income for the period was ₹597.62 million, with other comprehensive income net of taxes at ₹1.69 million.
The company's market cap is ₹23,274 crore, with a stock price of ₹2,225. The historical stock range has been between ₹2,664 / 992. Its Price-to-Earnings (P/E) ratio of 74.3 indicates a high valuation. The book value per share is ₹146, and it has a dividend yield of 0.39%. The ROCE is 28.1% and ROE is 21.1%. With a very low debt-to-equity ratio of 0.01, the company is minimally leveraged. However, it reports a negative net cash flow of ₹11.6 crore. The Piotroski score of 8.00 and the Graham Number of ₹314 show mixed financial indicators, while the Price-to-Book (P/B) ratio of 15.2 suggests the stock is trading at a premium.
Marksans Pharma Limited
2,545.27
Net Sales
320.15
Net Profit
2,626.79
Total Income
2,203.80
Expenditure
240
Current Price
10,876
Market Cap
For Marksans Pharma Limited, the latest financial data showcases impressive results. The company reported net sales of ₹2,545.27 million and total income of ₹2,626.79 million for the quarter. Expenditure was ₹2,203.80 million, resulting in a net profit of ₹320.15 million. EPS for continuing operations was ₹0.71. Additional financial details include other income of ₹81.52 million, finance costs of ₹2.83 million, and employee benefit expenses of ₹231.93 million. Depreciation and amortization expenses were ₹68.36 million. Current tax was ₹103.58 million and deferred tax amounted to ₹-0.74 million. Total comprehensive income for the period was ₹320.86 million, with other comprehensive income net of taxes at ₹0.71 million.
Currently valued at ₹10,876 crore, the company's stock price is ₹240. It has seen a price range of ₹243 / 93.8 over time. The stock's Price-to-Earnings (P/E) ratio is notably high at 32.7, implying a strong valuation. The book value per share is ₹45.6 and the dividend yield is 0.25%. ROCE is recorded at 20.6%, and ROE stands at 16.5%. The company maintains a very low debt-to-equity ratio of 0.12, though it has a negative net cash flow of ₹20.8 crore. The Piotroski score of 4.00 and the Graham Number of ₹86.9 suggest some caution, while the Price-to-Book (P/B) ratio of 5.27 reflects a premium valuation.
